In Vivo Accumulation of Regulatory T Cells Using Eliglustat-Loaded Cryogels.

Publication information:

Vitner EB, Bovone G, Jung W-H, Lou J, Hankenson H, Dacus MT, Binenbaum Y, Adu-Berchie K, Stafford AG, Sobral MC, et al. In Vivo Accumulation of Regulatory T Cells Using Eliglustat-Loaded Cryogels. Advanced healthcare materials. 2025:e2501529. doi:10.1002/adhm.202501529

Abstract

Regulatory T cells (T) maintain immune homeostasis and their adoptive transfer is being widely explored to mitigate inflammatory and autoimmune conditions. Here a biomaterial is developed to accumulate T at a specific anatomic location to bypass the need for ex vivo T isolation and adoptive transfer. It is first shown that eliglustat, an FDA-approved inhibitor of UDP-glucose ceramide glucosyltransferase, promotes T from both naïve and activated CD4 T cells in vitro. Click-crosslinked cryogels fabricated from alginate and collagen allow for a sustained release of CXCL10 or CXCL11, and when injected in subcutaneous tissues led to the enrichment of effector and memory T cells to the scaffolds. Loading eliglustat into these cryogels significantly enhances the local accumulation of T in vivo. These findings demonstrate that eliglustat-loaded cryogels offer a simple yet effective biomaterial strategy to boost T directly in vivo, potentially providing a targeted method to treat various inflammatory and autoimmune diseases.